BSS8_19_hinge.pdf
1.3 MB
The Scythians: Fierce warriors of Siberia and the Steppe (Drop 2 of 2)
The 2nd and final part to this drop on the Scythians, with this drop focusing mostly on their history and culture, through the eyes of figures such as Heroditus and Asclepyus, at a time when the Scythians were still very much a real and living fear, in the minds of those who encountered them!
The 2nd and final part to this drop on the Scythians, with this drop focusing mostly on their history and culture, through the eyes of figures such as Heroditus and Asclepyus, at a time when the Scythians were still very much a real and living fear, in the minds of those who encountered them!
Forwarded from sam fisher™
This media is not supported in your browser
VIEW IN TELEGRAM
And now for something completely different...
🔥1
jiac113.pdf
1.3 MB
Oxford Journal of Infectious Diseases: October 2022 issue (Drop 1 of 2)
In this months issue of the OJID:
Featured Editorial
1) Why Does Omicron Largely Spare Olfactory Function?
Polio
2) Polio by the Numbers—A Global Perspective
3) Doses of Inactivated Poliovirus Vaccine for Catch-up Vaccination in Older Infants
Dengue Fever
4) Development of Dengue With Increased Antibody Levels
5) Hyperinflammatory Syndrome, Natural Killer Cell Function, and Genetic Polymorphisms in the Pathogenesis of Dengue
Covid 19
6) Rapidly Increasing SARS Cov2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected During the 2020 Pandemic
7) Evidence for Human-to-Human Transmission of Hantavirus: A Systematic Review
8) Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination
9) Effectiveness of CoronaVac and BNT162b2 Vaccines Against SARS COV 2 Omicron BA.2 Infections in Hong Kong
In this months issue of the OJID:
Featured Editorial
1) Why Does Omicron Largely Spare Olfactory Function?
Polio
2) Polio by the Numbers—A Global Perspective
3) Doses of Inactivated Poliovirus Vaccine for Catch-up Vaccination in Older Infants
Dengue Fever
4) Development of Dengue With Increased Antibody Levels
5) Hyperinflammatory Syndrome, Natural Killer Cell Function, and Genetic Polymorphisms in the Pathogenesis of Dengue
Covid 19
6) Rapidly Increasing SARS Cov2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected During the 2020 Pandemic
7) Evidence for Human-to-Human Transmission of Hantavirus: A Systematic Review
8) Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination
9) Effectiveness of CoronaVac and BNT162b2 Vaccines Against SARS COV 2 Omicron BA.2 Infections in Hong Kong
jiac161.pdf
444.5 KB
Oxford Journal of Infectious Diseases: October 2022 issue (Drop 2 of 2)
Covid (cont'd)
1) Protection by Vaccines and Previous Infection Against the Omicron Variant of SARS COV 2
2) Cross-Neutralizing Activity Against Omicron Could Be Obtained in SARS-CoV-2 Convalescent Patients Who Received Two Doses of mRNA Vaccination
3) Omicron SARS COV 2 Neutralization by Immunoglobulin Preparations Manufactured From Plasma Collected in the United States and Europe
4) High Neutralizing Antibody Levels Against SARS COV 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster
5) Neutralizing Antibody Activity to SARS COV 2 Delta (B.1.617.2) and Omicron (B.1.1.529) After 1 or 2 Doses of BNT162b2 Vaccine in Infection-Naive and Previously Infected Individuals
6) Clinical Evaluation of SARS COV 2 Rapid Antigen Tests: South Africa
7) Delineating the Spread Omicron Using Wastewater in South Africa
8) Factors Associated With Human IgG Antibody Response to Anopheles albimanus Salivary Gland Extract, Artibonite Department 2017
Covid (cont'd)
1) Protection by Vaccines and Previous Infection Against the Omicron Variant of SARS COV 2
2) Cross-Neutralizing Activity Against Omicron Could Be Obtained in SARS-CoV-2 Convalescent Patients Who Received Two Doses of mRNA Vaccination
3) Omicron SARS COV 2 Neutralization by Immunoglobulin Preparations Manufactured From Plasma Collected in the United States and Europe
4) High Neutralizing Antibody Levels Against SARS COV 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster
5) Neutralizing Antibody Activity to SARS COV 2 Delta (B.1.617.2) and Omicron (B.1.1.529) After 1 or 2 Doses of BNT162b2 Vaccine in Infection-Naive and Previously Infected Individuals
6) Clinical Evaluation of SARS COV 2 Rapid Antigen Tests: South Africa
7) Delineating the Spread Omicron Using Wastewater in South Africa
8) Factors Associated With Human IgG Antibody Response to Anopheles albimanus Salivary Gland Extract, Artibonite Department 2017